Hikma Pharmaceuticals PLC 02 Group at a glance Diversified business 06 05 06 05 Revenue by business segment Revenue by region 1 Branded 41.0% 35.5% 1 Middle East and North Africa 49.7% 42.4% 2 Generics 35.9% 43.9% 2 United States 40.9% 49.8% 3 Injectables 21.3% 18.8% 3 Europe and ROW 9.3% 7.8% 4 Other 1.8% 1.8% 4 3 3 3 3 4 1 1 1 1 2 2 2 2 Geographic coverage Our markets R&D centres Manufacturing plants Hikma Pharmaceuticals PLC Group at a glance 03 Broad product portfolio Hikma sells 176 pharmaceutical products in 397 dosage strengths and forms in 40 countries.
26 of these products are sold under promotion and distribution agreements with, or licences from, 16 originator pharmaceutical companies and three generic pharmaceutical 1 companies.
The majority of Hikmas operations are in the the Middle East and North Africa, the United States and Europe.
1 Two additional in-licensed products were launched in early 2007 and a further five in-licensed products are pending launch.
2006 Branded Generics Injectables Revenue Revenue Revenue $130.1 million $113.7 million $67.6 million Products Products Products 83 43 50 branded generic products non-branded solid generic branded and non-branded including products injectable products including 18 8 products under licence products under licence Key markets Key markets Key markets Algeria, Jordan US Europe, MENA Saudi Arabia US Top products Top products Top products Amoclan ABC blue cefazolin Oprazole doxycycline cefotaxime Penamox lisinopril ceftriaxone Prograf lithium carb SR cefuroxime Suprax methocarbamol vancomycin
